Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT06075693
- Status
- Recruiting
Conditions
- Myotonic Dystrophy Type 1
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in brain activity and function. The purpose of this research is to learn about myotonic dystrophy by examining cerebrospinal fluid and brain activity in participants. The tests will be low risk and are well tolerated. The information that we gather from this study may help us evaluate, prevent, diagnose, treat, and improve our understanding of myotonic dystrophy. Funding Source- FDA OOPD
Key Dates
- Start date
- Aug 1, 2022
- Status verified
- Nov 2025
- Primary completion
- Aug 1, 2027
- Completion
- Aug 1, 2028
Study Design
- Enrollment
- 88 participants (estimated)
Arms
- Arm: LongitudinalWe will ask eligible volunteers to provide a CSF sample by a lumbar puncture procedure, a urine sample, undergo a cognitive assessment, and to undergo an MRI scan once per year for two years.
- Arm: SingleWe will ask eligible volunteers to provide a CSF sample by a lumbar puncture procedure, a urine sample, undergo a cognitive assessment, and to undergo an MRI scan once.
Primary Outcome Measure
Extracellular RNA splice variants in biofluids [ Time Frame: 5 years ]
Central Contacts
- Tamkin Shahraki, MD617-726-7506
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02129 | Thurman M Wheeler, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
Related Studies
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1PHASE3 · Enrolling By Invitation · Avidity Biosciences, Inc. · Los Angeles, California
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryRecruiting · University of Rochester · Rochester, New York
- Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic DystrophyRecruiting · University of Rochester · Rochester, New York